News
Latest news
- First patient enrolled in clinical trial of heart disease management software as a medical device (Japanese)
- Selected for the NEDO DTSU PCA phase; cumulative funding of JPY 3.5 billion supports clinical trials and global expansion of cardiac rehabilitation medical devices (Japanese)
- Series B final close: JPY 1.73 billion raised in total (Japanese)
- JPY 1.58 billion raised in the first close of Series B (Japanese)
- Our CEO Terashima chaired a symposium on remote cardiac rehabilitation at the cardiac rehabilitation society meeting (Japanese)
- Our CEO Terashima presented at an educational session on remote cardiac rehabilitation at the cardiac rehabilitation society meeting (Japanese)
- Our CEO Terashima received the Outstanding Young Investigator Award at the cardiac rehabilitation society meeting (Japanese)
- Selected for the fourth cohort of J-Startup CENTRAL (Japanese)
- CaTe advances its cardiac rehabilitation software as a medical device business with JPY 810 million in total funding since founding, following its Series A final close and selection for NEDO DTSU (Japanese)
- Employee wage increase announced
- JPY 400 million raised in the first close of Series A from JAFCO, Tokyo Wellness Impact Fund and others (Japanese)
- An additional JPY 40 million raised through J-KISS stock acquisition rights from a fund managed by Samurai Incubate Inc. (Japanese)
- Featured in a Coral Capital interview: “Cardiac rehabilitation at home” — why a practicing physician is developing a therapeutic app (Japanese)
-
Obtained a Type II Medical Device Marketing Authorization Holder license (13B2X10514) from the Tokyo Metropolitan Government
- JPY 100 million raised from Coral Capital through J-KISS stock acquisition rights (Japanese)